arrow
C

Carolina Gutiérrez

Lester and Sue Smith Breast Center
H指数:39
被引数:7,018

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC

整合空间组学揭示了美国黑人和美国白人TNBC患者中不同的促进肿瘤的多细胞生态位和免疫抑制机制

2025-07-170
OA
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer
2023-08-014
OA
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+Breast Cancer
2023-05-174
OA
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

与乳腺癌相应切除标本相比,核心活检样本的Ki67评分系统更高: 一项多运营商和多机构研究

2022-10-0125
OAAI
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
2021-05-277
OAAI
Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study
2020-02-150
PRE
Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer
2020-02-150
PRE
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

FOXA1上调促进内分泌耐药乳腺癌增强子和转录重编程

2019-12-11104
OAAI
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration
2019-07-0876
OAAI
The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models
2019-07-010
PRE
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+breast cancer
2019-06-0140
OAAI
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
2019-04-30100
OAAI